AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine

NORTH CHICAGO, Ill., March 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULI...

Related Keywords

United States ,American , ,Instagram ,Linkedin ,American Migraine Foundation ,Twitter ,Drug Administration ,International Classification Of Headache Disorders ,Exchange Commission ,International Burden Of Migraine Study ,Youtube ,European Union ,Allergan ,Facebook ,United States Focused ,European Union Focused ,Prescribing Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Classification Committee ,International Headache Society ,International Classification ,Headache Disorders ,Vie Announces Positive Phase ,Only Oral ,Antagonist Specifically Developed ,Preventive Treatment ,Facts About ,American Migraine ,Pain Headache ,Neurol Neurosurg ,Chronic Migraine Epidemiology ,International Burden ,Migraine Study ,Mayo Clin ,